# Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

> **NCT00940225** · PHASE2 · COMPLETED · sponsor: **Exelixis** · enrollment: 730 (actual)

## Conditions studied

- Solid Tumors
- Cancer

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00940225
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-05
- **Final completion:** 2014-06
- **Target enrollment:** 730 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00940225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00940225, "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00940225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*